Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
F-Prime Capital
Biotech
RNA biotech emerges with $52M and clinical rare disease asset
Arnatar currently touts seven assets, with six preclinical programs that range across cardiometabolic, inflammatory and CNS conditions.
Gabrielle Masson
Aug 25, 2025 10:13am
Novartis inks $175M option deal for Sironax’s BBB tech
Jul 9, 2025 10:29am
Atalanta loads crossbow with $97M, 2 Big Pharmas in tow
Jan 28, 2025 7:00am
Tenvie takes off with $200M, assets and exec from Denali
Jan 8, 2025 8:00am
2 eye disease biotechs merge, set sights on FDA approval
Dec 12, 2024 11:05am
Arch-backed obesity biotech launches with $290M
Apr 18, 2024 7:00am
